Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03091920 · ClinicalTrials.gov registry record · Phase 2
Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
A Phase 2 study, sponsored by Cyclerion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03091920 is a Phase 2 study that has completed, run by Cyclerion Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT03091920, a Phase 2 study, has completed, sponsored by Cyclerion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
To compare the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects of 2 treatment regimens of IW-1973 tablet (40 mg per day) administered orally for 2 weeks to patients with stable type 2 diabetes mellitus and hypertension.
Interventions
- DRUG Placebo
- DRUG IW-1973
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2017-08-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03091920
The ClinicalTrials.gov registry entry for NCT03091920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclerion Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03091920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03091920 about?
NCT03091920 is a clinical study titled "Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension". To compare the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects of 2 treatment regimens of IW-1973 tablet (40 mg per day) administered orally for 2 weeks to patients with stable type 2 diabetes mellitus and hypertension.
What is the current status of trial NCT03091920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2017-02-28. Estimated completion is 2017-08-03.
What interventions are being tested in trial NCT03091920?
The interventions under investigation include: Placebo (DRUG), IW-1973 (DRUG).
Who is sponsoring clinical trial NCT03091920?
This trial is sponsored by Cyclerion Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.